TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.

TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.

TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.

JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.

TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.

TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.

TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.

TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.